REPORT ON DIPOZAG 30 AND FLEPGO 100 AT THE DEPARTMENT OF ANDROLOGY, MILITARY CENTRAL HOSPITAL

On October 16, 2026, at the Andrology Department of Military Central Hospital, Medbolide Pharma SJC successfully organized the “Seminar Introducing DIPOZAG 30 (Dapoxetine 30 mg) – FLEPGO 100 (Avanafil 100 mg).

Through the seminar, doctors had the opportunity to gain a deeper understanding of DIPOZAG 30 (Dapoxetine 30 mg)—the only oral active ingredient approved by the EMA for the treatment of premature ejaculation—with the following key features:

• The only oral medication approved for the treatment of premature ejaculation (PE)
• Rapid absorption – rapid elimination => Fast-acting, minimal accumulation, optimal therapeutic efficacy
• Few side effects, no risk of drug dependence
• Effective and well-tolerated in men with moderate to severe premature ejaculation
• Effective in 67.5% of men with primary premature ejaculation who did not respond to prior sertraline therapy

FLEPGO 100, containing 100 mg of the active ingredient avanafil, is a new-generation PDE5 inhibitor that selectively and specifically inhibits PDE5 in penile erectile tissue, helping to:

• Fastest onset of erection—within 15 minutes after taking the medication
• Fewest side effects among PDE5 inhibitors
• Twice as effective in treating erectile dysfunction as Sildenafil across all severity levels
• Effective in patients with dyslipidemia, diabetes, hypertension, etc., who have failed other erectile dysfunction treatments
• Shows good response in patients with severe erectile dysfunction and those who have undergone prostatectomy

Following the seminar, the doctors spoke highly of the DIPOZAG 30 and FLEPGO 100 products. Medbolide also expressed its gratitude to the doctors and hopes to continue partnering with the Andrology Department at Military Central Hospital to provide effective treatment solutions and improve patients’ quality of life.